Oral psöralenlerle birlikte ultraviyole ışığı tedavisi, psöriasis, vitiligo ve benzeri hastalıkların tedavisinde yaygın olarak kullanılmaktadır. En sık görülen yan etkiler artmış fotosensiviteye bağlı bulantı, kusma, kaşıntı ve eritemdir. Psörolanlerin hepatotoksik olmadığı ama geçici karaciğer enzim yükseklikleri yapabileceği kabul edilmektedir. Biz burada hepatotoksisite varlığını biyopsi ile gösterdiğimiz iki olguyu sunuyoruz.
Stephens RB, Cooper A. Hepatitis from 5-methoxypsoralen occuring in a patient with previous flucloxacillin hepatitis. Australas J Dermatol 1999;40:217-9.
McNeedly W, Goa KL. 5-methoxypsoralen. A review of its effect in psoriasis and vitiligo. Drugs 1998;56:667-90.
Nyfors A, Dahl-Nyfors B, Hopwoop D. Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): findings before and after 1 year of therapy in twelve patients. A blind study and review of literature on hepatotoxicity of PUVA. J Am Acad Dermatol 1986;14:43-8.
Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005;152:597-615.
Pariser DM, Wyles RJ. Toxic hepatitis from oral methoxsalen photochemotherapy (PUVA). J Am Acad Dermatol 1980;3:248-50.
Berg M, Ros AM. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5- methoxypsoralen. Photodermatol Photoimmunol Photomed 1994;10:217-20.
Methoxypsoralen-related hepatotoxicity: Two cases reports
Psoralen and ultraviolet A therapy has been widely used in the treatment of psoriasis, vitiligo and similar diseases. The most common side effects are nausea, vomiting, pruritus, and erythema, due to increased photosensitivity. It was accepted that psoralens are not hepatotoxic but can cause transient liver enzyme elevations. Here, we present two cases in which we demonstrated hepatotoxicity with biopsy.
Stephens RB, Cooper A. Hepatitis from 5-methoxypsoralen occuring in a patient with previous flucloxacillin hepatitis. Australas J Dermatol 1999;40:217-9.
McNeedly W, Goa KL. 5-methoxypsoralen. A review of its effect in psoriasis and vitiligo. Drugs 1998;56:667-90.
Nyfors A, Dahl-Nyfors B, Hopwoop D. Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): findings before and after 1 year of therapy in twelve patients. A blind study and review of literature on hepatotoxicity of PUVA. J Am Acad Dermatol 1986;14:43-8.
Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005;152:597-615.
Pariser DM, Wyles RJ. Toxic hepatitis from oral methoxsalen photochemotherapy (PUVA). J Am Acad Dermatol 1980;3:248-50.
Berg M, Ros AM. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5- methoxypsoralen. Photodermatol Photoimmunol Photomed 1994;10:217-20.